portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 Duyiwei Biological H1 Earnings Up10%
 
CreateTime:2011-08-18     Source:CapitalVue Editor:xujintao
Text Size:       
 

August 17-- Gansu Duyiwei Biological Pharmaceutical (002219.SZ) posted a 9.55-percent increase in net profit from the first half of 2011 to 31.58 million yuan, with earnings per share of 0.08 yuan, reports p5w.net, citing a company filing. Revenue rose 6.97 percent year-on-year to 146 million yuan during the reporting period.

Duyiwei Pharmaceutical predicts its net profit will change by between negative 5 percent to 10 percent to between 48-55 million yuan in the first three quarters this year.

Duyiwei Pharmaceutical is engaged in the research, development, manufacture and sale of traditional Chinese medicines. Its products are divided into four categories: analgesics and haemostatic drugs including Duyiwei Capsules, drugs for replenishing Qi, nourishing blood and tranquillization including Shenqi Wuweizi Tablets, cardiovascular drugs such as Maiping Tablets, as well as drugs for urinary and reproductive systems such as Qianlie Antong Tablets.


Related Reports
China Pharmaceutical Glass Packaging Industry Report, 2014-2017
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1